Inventor
MENNITI FRANK S
US23 patents
⚠️ This page may combine multiple inventors who share the name “MENNITI FRANK S”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PFIZER
8 patentsUS6821985B2Nov 23, 2004
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
PFIZER65 citations94
US6667317B2Dec 23, 2003
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
PFIZER60 citations94
US6258827B1Jul 10, 2001
Combinations for the treatment of parkinsonism containing selective NMDA antagonists
PFIZER43 citations92
US6136812AOct 24, 2000
Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
PFIZER61 citations92
US7078529B2Jul 18, 2006
Imidazole derivatives
PFIZER8 citations70
US6756385B2Jun 29, 2004
Imidazole derivatives
PFIZER11 citations68
US6958351B2Oct 25, 2005
NMDA NR2B antagonists for treatment
PFIZER5 citations57
US7019016B2Mar 28, 2006
NMDA NR2B antagonists for treatment
PFIZER0 citations50
CADENT THERAPEUTICS INC
7 patentsUS10973825B2Apr 13, 2021
Thienopyrimidinone NMDA receptor modulators and uses thereof
CADENT THERAPEUTICS INC6 citations84
US10626122B2Apr 21, 2020
Heteroaromatic NMDA receptor modulators and uses thereof
CADENT THERAPEUTICS INC8 citations84
US10500205B2Dec 10, 2019
Thienopyrimidinone NMDA receptor modulators and uses thereof
CADENT THERAPEUTICS INC10 citations84
US11541057B2Jan 3, 2023
Thienopyrimidinone NMDA receptor modulators and uses thereof
CADENT THERAPEUTICS INC1 citations73
US11236104B2Feb 1, 2022
Heteroaromatic NMDA receptor modulators and uses thereof
CADENT THERAPEUTICS INC4 citations73
US11116749B2Sep 14, 2021
Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B
CADENT THERAPEUTICS INC0 citations62
US10781174B2Sep 22, 2020
N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B
CADENT THERAPEUTICS INC1 citations62
NOVARTIS AG
5 patentsUS12161624B2Dec 10, 2024
Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B
NOVARTIS AG1 citations73
US12358929B2Jul 15, 2025
NMDA receptor modulators and uses thereof
NOVARTIS AG0 citations62
US12162890B2Dec 10, 2024
Heteroaromatic NMDA receptor modulators and uses thereof
NOVARTIS AG0 citations62
US12145909B2Nov 19, 2024
N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B
NOVARTIS AG1 citations62
US11648253B2May 16, 2023
Thienopyrimidinone NMDA receptor modulators and uses thereof
NOVARTIS AG0 citations62